# Abbott Stock Financials

ABT | Stock | ## USD 111.48 0.99 0.90% |

**B**in 2022, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop slightly above 10.6

**B**in 2022.

Abbott | Select Account or Indicator |

With this module, you can analyze Abbott financials for your investing period. You should be able to track the changes in Abbott Laboratories individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

### Abbott Most Recent Estimates

Quarterly Earnings Growth YOY 0.73 | EPS Estimate Next Quarter 0.98 | Diluted Eps 4.79 | EPS Estimate Current Year 5.04 | EPS Estimate Next Year 4.68 | EPS Estimate Current Quarter 1.12 | Earnings Share 4.79 |

## Revenues | ## 37.89 Billion |

Understanding current and past Abbott Laboratories Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Abbott Laboratories' financial statements are interrelated, with each one affecting the others. For example, an increase in Abbott Laboratories' assets may result in an increase in income on the income statement.

The fundamental analysis of Abbott Laboratories is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Abbott Laboratories includes many different criteria found on its balance sheet. For example, investors should never minimize Abbott Laboratories' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Abbott Laboratories' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Abbott Laboratories.

### Abbott Laboratories Cash

Chance Of Financial Distress

Less than 5

Abbott Laboratories has

**less than 5 (%) percent**chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Abbott Laboratories stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More InfoThe data published in Abbott Laboratories' official financial statements usually reflect Abbott Laboratories' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Abbott Laboratories. For example, before you start analyzing numbers published by Abbott accountants, it's critical to develop an understanding of what Abbott Laboratories' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.

Please note, the presentation of Abbott Laboratories' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Abbott Laboratories' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Abbott Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Abbott Laboratories. Please utilize our Beneish M Score to check the likelihood of Abbott Laboratories' management to manipulate its earnings.

## Abbott Laboratories Company Summary

Abbott Laboratories competes with Abiomed, Allied Healthcare, National Cinemedia, Rocket Lab, and Agilent Technologies. Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois. Abbott Laboratories operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 113000 people.Foreign Associates | |

Specialization | Healthcare, Medical Devices |

Instrument | USA Stock View All |

Exchange | New York Stock Exchange |

CIK Number | 0000001800 |

ISIN | US0028241000 |

CUSIP | 002824100 |

Region | North America |

Location | Illinois; U.S.A |

Business Address | 100 Abbott Park |

Sector | Healthcare |

Industry | Medical Devices |

Benchmark | DOW |

Website | www.abbottinvestor.com |

Phone | 224 667 6100 |

Currency | USD - US Dollar |

You should never invest in Abbott Laboratories without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Abbott Stock, because this is throwing your money away. Analyzing the key information contained in Abbott Laboratories' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

## Abbott Laboratories Key Financial Ratios

Generally speaking, Abbott Laboratories' financial ratios allow both analysts and investors to convert raw data from Abbott Laboratories' financial statements into concise, actionable information that can be used to evaluate the performance of Abbott Laboratories over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Abbott Laboratories reports annually and quarterly.Return On Asset | 8.56 % | |||

Profit Margin | 18.78 % | |||

Operating Margin | 22.96 % |

## Abbott Laboratories Key Balance Sheet Accounts

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Inventories | 3.6 B | 3.8 B | 4.32 B | 5.01 B | 5.16 B | 4.21 B | |

Receivables | 5.25 B | 5.18 B | 5.42 B | 6.41 B | 6.49 B | 6.57 B | |

Accounts Payable | 2.4 B | 2.98 B | 3.25 B | 3.95 B | 4.41 B | 4.76 B | |

Total Assets | 76.25 B | 67.17 B | 67.89 B | 72.55 B | 75.2 B | 74.56 B | |

Current Assets | 20.15 B | 14.63 B | 15.67 B | 20.44 B | 24.24 B | 21.33 B | |

Assets Non Current | 56.1 B | 52.54 B | 52.22 B | 52.11 B | 50.96 B | 50.01 B | |

Cash and Equivalents | 9.61 B | 4.09 B | 4.14 B | 7.15 B | 9.8 B | 8.81 B | |

Total Debt | 27.92 B | 19.57 B | 18.14 B | 18.75 B | 18.05 B | 19.17 B | |

Debt Current | 714 M | 207 M | 1.48 B | 220 M | 754 M | 773.84 M | |

Debt Non Current | 27.21 B | 19.36 B | 16.66 B | 18.53 B | 17.3 B | 17.66 B | |

Shareholders Equity | 31.1 B | 30.72 B | 31.3 B | 33 B | 36.02 B | 34.88 B | |

Inventory | 3.6 B | 3.8 B | 4.32 B | 5.01 B | 5.16 B | 4.78 B | |

Investments | 2.95 B | 883 M | 897 M | 821 M | 1.27 B | 1.34 B | |

Total Liabilities | 45.15 B | 36.45 B | 36.59 B | 39.55 B | 39.17 B | 39.68 B | |

Current Liabilities | 8.91 B | 9.01 B | 10.86 B | 11.91 B | 13.11 B | 11.43 B | |

Tax Assets | 1.94 B | 1.89 B | 3.08 B | 3.73 B | 5.21 B | 4.26 B | |

Tax Liabilities | 309 M | 305 M | 226 M | 362 M | 306 M | 304.25 M |

## Abbott Laboratories Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Abbott Laboratories' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Direct Expenses | 12.34 B | 12.71 B | 13.23 B | 15 B | 18.54 B | 15.17 B | |

Consolidated Income | 477 M | 2.37 B | 3.69 B | 4.5 B | 7.07 B | 5.8 B | |

Cost of Revenue | 12.41 B | 12.71 B | 13.23 B | 15 B | 18.54 B | 16.44 B | |

Gross Profit | 14.98 B | 17.87 B | 18.67 B | 19.61 B | 24.54 B | 21.45 B | |

Interest Expense | 904 M | 826 M | 670 M | 546 M | 533 M | 546.16 M | |

Net Income | 477 M | 2.37 B | 3.69 B | 4.5 B | 7.07 B | 5.8 B | |

Operating Expenses | 13.42 B | 14.22 B | 14.14 B | 14.25 B | 16.11 B | 15.06 B | |

Operating Income | 1.56 B | 3.65 B | 4.53 B | 5.36 B | 8.43 B | 9.09 B | |

Revenues | 27.39 B | 30.58 B | 31.9 B | 34.61 B | 43.08 B | 37.89 B | |

Income Tax Expense | 1.88 B | 539 M | 390 M | 497 M | 1.14 B | 909.16 M |

## Abbott Laboratories Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Abbott Laboratories. It measures of how well Abbott is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Abbott Laboratories brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Abbott had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Abbott Laboratories has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Capital Expenditure | (1.14 B) | (1.39 B) | (1.64 B) | (2.18 B) | (1.89 B) | (2.03 B) | |

Depreciation Amortization and Accretion | 3.02 B | 3.28 B | 3.01 B | 3.33 B | 3.54 B | 3.34 B | |

Net Cash Flow or Change in Cash and Cash Equivalents | (9.21 B) | (5.56 B) | 16 M | 2.98 B | 2.96 B | 3.19 B | |

Net Cash Flow Business Acquisitions and Disposals | (8.44 B) | (6 M) | (122 M) | 16 M | (53 M) | (57.18 M) | |

Issuance Purchase of Equity Shares | 233 M | 33 M | (420 M) | (158 M) | (2.04 B) | (2.1 B) | |

Issuance Repayment of Debt Securities | (2.94 B) | (8.45 B) | (1.6 B) | (50 M) | (248 M) | (254.53 M) | |

Payment of Dividends and Other Cash Distributions | (1.85 B) | (1.97 B) | (2.27 B) | (2.56 B) | (3.2 B) | (3.45 B) | |

Net Cash Flow from Financing | (5.28 B) | (10.39 B) | (4.29 B) | (2.78 B) | (5.49 B) | (5.64 B) | |

Net Cash Flow from Investing | (9.62 B) | (1.36 B) | (1.81 B) | (2.21 B) | (2.01 B) | (2.17 B) | |

Net Cash Flow Investment Acquisitions and Disposals | (81 M) | (58 M) | (82 M) | (73 M) | (96 M) | (103.58 M) | |

Net Cash Flow from Operations | 5.57 B | 6.3 B | 6.14 B | 7.9 B | 10.53 B | 9.12 B | |

Effect of Exchange Rate Changes on Cash | 116 M | (116 M) | (16 M) | 71 M | (70 M) | (75.53 M) | |

Share Based Compensation | 406 M | 477 M | 519 M | 546 M | 640 M | 574.42 M |

## Abbott Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Abbott Laboratories's current stock value. Our valuation model uses many indicators to compare Abbott Laboratories value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Abbott Laboratories competition to find correlations between indicators driving Abbott Laboratories's intrinsic value. More Info.Abbott Laboratories is number one stock in ebitda category among related companies. It is number one stock in profit margin category among related companies . The ratio of EBITDA to Profit Margin for Abbott Laboratories is about 736,421,725 . Abbott Laboratories Earnings Before Interest Taxes and Depreciation Amortization EBITDA are comparatively stable at the moment as compared to the past year. Abbott Laboratories reported Earnings Before Interest Taxes and Depreciation Amortization EBITDA of 12.28 Billion in 2021. Comparative valuation analysis is a catch-all model that can be used if you cannot value Abbott Laboratories by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Abbott Laboratories' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Abbott Laboratories' earnings, one of the primary drivers of an investment's value.## Abbott Laboratories Systematic Risk

Abbott Laboratories' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Abbott Laboratories volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.

The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Abbott Laboratories correlated with the market. If Beta is less than 0 Abbott Laboratories generally moves in the opposite direction as compared to the market. If Abbott Laboratories Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Abbott Laboratories is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Abbott Laboratories is generally in the same direction as the market. If Beta > 1 Abbott Laboratories moves generally in the same direction as, but more than the movement of the benchmark..

## About Abbott Laboratories Financials

What exactly are Abbott Laboratories Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Abbott Laboratories' income statement, its balance sheet, and the statement of cash flows. Potential Abbott Laboratories investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Abbott Laboratories investors may use each financial statement separately, they are all related. The changes in Abbott Laboratories's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Abbott Laboratories's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Abbott Laboratories is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Abbott grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

## Abbott Laboratories Thematic Clasifications

Abbott Laboratories is part of several thematic ideas from Obamacare Repeal to Drugs. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas

Obamacare Repeal | View | ||

Drugs | View | ||

Compulsion | View | ||

SRI Sustainable Growth | View |

## Abbott Laboratories August 13, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Abbott Laboratories help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Abbott Laboratories. We use our internally-developed statistical techniques to arrive at the intrinsic value of Abbott Laboratories based on widely used predictive technical indicators. In general, we focus on analyzing Abbott Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Abbott Laboratories's daily price indicators and compare them against related drivers.

Downside Deviation | 1.46 | |||

Information Ratio | 0.0021 | |||

Maximum Drawdown | 7.79 | |||

Value At Risk | (2.61) | |||

Potential Upside | 2.72 |

Please continue to Trending Equities. Note that the Abbott Laboratories information on this page should be used as a complementary analysis to other Abbott Laboratories' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

## Complementary Tools for Abbott Stock analysis

When running Abbott Laboratories price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.

My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | Go | |

Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges | Go | |

Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets | Go | |

Shere PortfolioTrack or share privately all of your investments from the convenience of any device | Go | |

Commodity Channel IndexUse Commodity Channel Index to analyze current equity momentum | Go | |

Stock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | Go | |

Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | Go | |

Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | Go | |

Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios | Go | |

Bollinger BandsUse Bollinger Bands indicator to analyze target price for a given investing horizon | Go | |

Transaction HistoryView history of all your transactions and understand their impact on performance | Go | |

Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios | Go | |

Analyst RecommendationsAnalyst recommendations and target price estimates broken down by several categories | Go |

Is Abbott Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abbott Laboratories. If investors know Abbott will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abbott Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth YOY 0.73 | Market Capitalization 193.5 B | Quarterly Revenue Growth YOY 0.1 | Return On Assets 0.0896 | Return On Equity 0.24 |

The market value of Abbott Laboratories is measured differently than its book value, which is the value of Abbott that is recorded on the company's balance sheet. Investors also form their own opinion of Abbott Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Abbott Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abbott Laboratories' market value can be influenced by many factors that don't directly affect Abbott Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Abbott Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine Abbott Laboratories value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abbott Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.